Liang Yingying, Turcan Sevin
Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Biomedicines. 2022 Jan 19;10(2):211. doi: 10.3390/biomedicines10020211.
Epigenetic drugs are used for the clinical treatment of hematologic malignancies; however, their therapeutic potential in solid tumors is still under investigation. Current evidence suggests that epigenetic drugs may lead to antitumor immunity by increasing antigen presentation and may enhance the therapeutic effect of immune checkpoint inhibitors. Here, we highlight their impact on the tumor epigenome and discuss the recent evidence that epigenetic agents may optimize the immune microenvironment and promote antiviral response.
表观遗传药物用于血液系统恶性肿瘤的临床治疗;然而,它们在实体瘤中的治疗潜力仍在研究中。目前的证据表明,表观遗传药物可能通过增加抗原呈递来引发抗肿瘤免疫,并可能增强免疫检查点抑制剂的治疗效果。在此,我们强调它们对肿瘤表观基因组的影响,并讨论近期有关表观遗传药物可能优化免疫微环境并促进抗病毒反应的证据。